- Entry
- $13.36
- Final
- $11.74 -12.2%
- Target
- —
- Score
- -1.00
**Positions:** Long NTLA. This is a fundamental and structural analysis of a major dislocation in the biotech sector that materialized today (Saturday, June 13). The market has fundamentally mispriced **Intellia Therapeutics (NASDAQ: NTLA)** due to a recent secondary offering, creating a highly asymmetric risk/reward profile ahead of Monday's opening. Here is the objective breakdown of the clinical data and the market mechanics. # 1. The Technology: In-Vivo vs. Ex-Vivo To understand the valuation gap, you have to separate the two …
— ORIGINAL POST ·
NTLA Deep Dive: Market Mispricing After Flawless Phase 3 CRISPR Data Published in NEJM Today - 35-40% short interest
· r/Shortsqueeze
· Jun 14, 2026